The Doris Duke Foundation’s long biotechnology bet is paying off after a five-year winter. The $2.2 billion portfolio has steadily expanded its exposure to health and life sciences as part of a broader effort to invest in areas tied to the foundation’s priorities. And this yearslong push to align the New York-based charitable organization’s endowment with its mission is starting to show results as biotech rebounds.
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.